
Release date: 2026-05-14 15:43:16 Article From: Lucius Laos Recommended: 15
Before and during treatment with ritlecitinib, you must contact your doctor immediately if you experience any signs of infection, such as fever, sweating, chills, muscle aches, cough, difficulty breathing, coughing up blood, unexplained weight loss, diarrhea, abdominal pain, burning sensation when urinating or frequent urination, extreme fatigue, etc. Ritlecitinib may lower your body's ability to fight infections, may worsen an existing infection, or increase your risk of developing new infections. If you have diabetes or are over 65 years of age, your risk of infection is higher. Additionally, if you have ever had tuberculosis or have been in close contact with someone who has tuberculosis, your doctor will perform a tuberculosis test before and during treatment.
If you have ever had or currently have any of the following conditions, be sure to tell your doctor: any form of herpes infection (such as chickenpox or shingles), as ritlecitinib may cause it to recur; be alert for painful blistering rashes; hepatitis B or C, your doctor will perform the necessary tests; any type of cancer, it is not yet known whether ritlecitinib increases the risk of cancer, and your doctor will assess whether regular skin checks are needed; a history of blood clots in the legs or lungs, if you experience leg pain/swelling, chest pain, or difficulty breathing, these may be signs of a blood clot; a history of blood clots in the eyes or arteries of the heart, seek immediate medical attention if you experience sudden vision changes, chest pain, or difficulty breathing.
Before using ritlecitinib, tell your doctor about all other medications you are taking, especially those used to treat anxiety or insomnia (e.g., midazolam), heart rhythm problems (e.g., quinidine), gout (e.g., colchicine), organ transplant rejection (e.g., cyclosporine), migraine, psychiatric disorders, asthma, muscle cramps, or pulmonary fibrosis. Ritlecitinib may increase the blood levels of these drugs. For women of childbearing potential, effective contraception must be used during treatment and for at least one month after stopping the medication. Pregnant or breastfeeding women are prohibited from using this drug. If you are a child under 12 years of age, this drug is not approved for use. Additionally, ritlecitinib contains lactose. If you are intolerant to certain sugars, please consult your doctor.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3322025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5422024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3242025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3392025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3172025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3722025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3122025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2912025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643